scholarly article | Q13442814 |
P50 | author | Elizabeth A Raetz | Q114529750 |
Michael J Borowitz | Q117236346 | ||
Leonard A Mattano | Q117271270 | ||
Julie Gastier-Foster | Q30830859 | ||
Stephen P Hunger | Q64215088 | ||
Mignon L Loh | Q64215090 | ||
Nyla A Heerema | Q89317565 | ||
Brent L Wood | Q89862846 | ||
Naomi Winick | Q91287117 | ||
Wanda L Salzer | Q95949129 | ||
Cheryl L. Willman | Q110811050 | ||
P2093 | author name string | Meenakshi Devidas | |
Si Chen | |||
William L Carroll | |||
Eric C Larsen | |||
Catherine Cole | |||
Alisa Eicher | |||
Andrew A Carroll | |||
Mark Sorenson | |||
Maureen Haugan | |||
P2860 | cites work | Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples | Q24569561 |
Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia | Q31960231 | ||
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. | Q32061751 | ||
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. | Q33645862 | ||
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia | Q34314927 | ||
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia | Q34707586 | ||
Biology, risk stratification, and therapy of pediatric acute leukemias: an update | Q34764504 | ||
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. | Q35976588 | ||
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group | Q36058255 | ||
Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia | Q36105259 | ||
Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group | Q36478435 | ||
Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institut | Q36678136 | ||
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study | Q36713493 | ||
Predicting relapse risk in childhood acute lymphoblastic leukaemia | Q38117685 | ||
Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group | Q40748162 | ||
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia | Q40961746 | ||
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group | Q44280928 | ||
Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia | Q44405561 | ||
Corticosteroids, behavior, and quality of life in children treated for acute lymphoblastic leukemia; a multicentered trial | Q45257171 | ||
Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. | Q46021126 | ||
Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial | Q46543487 | ||
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia | Q46638043 | ||
Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group | Q47323159 | ||
Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. | Q50537461 | ||
Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. | Q52888294 | ||
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. | Q52906615 | ||
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. | Q52906689 | ||
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. | Q52966697 | ||
Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy | Q64225643 | ||
Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia | Q69728140 | ||
Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia | Q73666578 | ||
P433 | issue | 20 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | lymphoblastic leukemia | Q18553852 |
leukemia | Q29496 | ||
dexamethasone | Q422252 | ||
methotrexate | Q422232 | ||
P304 | page(s) | 2380-2388 | |
P577 | publication date | 2016-04-25 | |
P1433 | published in | Journal of Clinical Oncology | Q400292 |
P1476 | title | Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232 | |
P478 | volume | 34 |
Q46476461 | A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia |
Q91565663 | Acute lymphoblastic leukaemia |
Q39396416 | Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study |
Q47837260 | Agents in Development for Childhood Acute Lymphoblastic Leukemia |
Q47955491 | An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia |
Q64066039 | Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models |
Q92282088 | Cancer Treatment-Related Infertility: A Critical Review of the Evidence |
Q89585955 | Causes of Death in Childhood Acute Lymphoblastic Leukemia at Hue Central Hospital for 10 Years (2008-2018) |
Q92627035 | Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia |
Q92176231 | Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia |
Q59136673 | Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP) |
Q47255380 | Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232. |
Q47706549 | Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia. |
Q47199612 | DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol. |
Q88891952 | Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622 |
Q57462209 | Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients |
Q59330178 | Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia |
Q48272108 | Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. |
Q64117250 | Efficacy and association analysis of high-dose methotrexate in the treatment of children with acute lymphoblastic leukemia |
Q49711977 | Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG). |
Q51738618 | Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). |
Q33774499 | Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia |
Q46844249 | Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy |
Q52717677 | Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. |
Q40044204 | High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG. |
Q50098629 | How is the Ph-like signature being incorporated into ALL therapy? |
Q96693732 | Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial |
Q91451448 | Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk |
Q38769075 | Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group |
Q90024651 | Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group |
Q57284581 | Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization |
Q53713010 | Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. |
Q49497206 | Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study |
Q92826242 | Maternal Haplotypes in DHFR Promoter and MTHFR Gene in Tuning Childhood Acute Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS) |
Q52735368 | Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. |
Q36414199 | Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group |
Q38813392 | Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue. |
Q90226917 | Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics |
Q39368957 | Novel therapy for childhood acute lymphoblastic leukemia |
Q91045688 | PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia |
Q49951910 | Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. |
Q40332285 | Potential Route of Transmission for Trichodysplasia Spinulosa Polyomavirus |
Q89768692 | Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population |
Q45985775 | Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens. |
Q64886346 | Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients. |
Q91287120 | Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905 |
Q95730173 | Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial |
Q50016386 | Recent Developments in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia |
Q45105040 | Recent advances in the management of pediatric acute lymphoblastic leukemia |
Q46103668 | Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing |
Q64074844 | Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG |
Q47103786 | Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma |
Q45072276 | Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials |
Q30240217 | T-cell acute lymphoblastic leukemia. |
Q47564553 | TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children |
Q61445248 | The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL |
Q49088868 | The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients |
Q48369402 | Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. |
Q91997669 | Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group |
Q90606756 | Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens |
Q52626221 | Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16. |
Q47258794 | Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions? |
Q102058897 | Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07 |
Q92282037 | Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia |
Q30397448 | What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning? |
Q57020347 | Will My Child Do Better if She Enrolls in a Clinical Trial? |
Q91595896 | Zebrafish patient avatars in cancer biology and precision cancer therapy |
Search more.